CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 332 enrolled
Drug / intervention
3% DE-089 ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01240382
NCT01240382Phase 3Completed

Double-masked Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Multi-center Study, in Comparison to 0.1% Sodium Hyaluronate Ophthalmic Solution) - Phase III Confirmatory Study -

Santen Pharmaceutical Co., Ltd.·interventional·Posted Nov 15, 2010·Updated Aug 13, 2014

In Brief

A Phase 3 clinical trial evaluating 3% DE-089 ophthalmic solution and 0.1% sodium hyaluronate ophthalmic solution for Dry Eye. Completed, enrolled 332 participants across 1 site.

Detailed Summary

To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 15, 2010
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Posted 15.6 years ago

Interventions

3% DE-089 ophthalmic solutiondrug

0.1% sodium hyaluronate ophthalmic solutiondrug